High Court discusses plausibility requirement for sufficiency of patent disclosure | Practical Law

High Court discusses plausibility requirement for sufficiency of patent disclosure | Practical Law

The High Court has held that a second medical use patent owned by Lilly for the treatment of attention-deficit/hyperactivity disorder (ADHD) by the drug atomoxetine was valid. (Actavis Group PTC EHF and another v Eli Lilly and Company 2015] EWHC 3294 (Pat), 16 November 2015.)

High Court discusses plausibility requirement for sufficiency of patent disclosure

Practical Law UK Legal Update Case Report 7-620-5855 (Approx. 3 pages)

High Court discusses plausibility requirement for sufficiency of patent disclosure

by Practical Law IP&IT
Published on 25 Nov 2015 • United Kingdom
The High Court has held that a second medical use patent owned by Lilly for the treatment of attention-deficit/hyperactivity disorder (ADHD) by the drug atomoxetine was valid. (Actavis Group PTC EHF and another v Eli Lilly and Company 2015] EWHC 3294 (Pat), 16 November 2015.)